Ombitasvir, paritaprevir, ritonavir and dasabuvir and Reyvow
Determining the interaction of Ombitasvir, paritaprevir, ritonavir and dasabuvir and Reyvow and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.GENERALLY AVOID: Coadministration with lasmiditan may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) transporters. The proposed mechanism, based on in vitro data, involves decreased clearance due to inhibition of P-gp and BCRP by lasmiditan. The clinical relevance is unknown. MANAGEMENT: Concomitant use of lasmiditan with drugs that are P-gp and/or BCRP substrates should be avoided when possible. If coadministration is required, patients should be carefully monitored for increased adverse reactions of these drugs and dosing adjusted as necessary. References "Product Information. Reyvow (lasmiditan)." Lilly, Eli and Company, Indianapolis, IN.
Professional:GENERALLY AVOID: Coadministration with lasmiditan may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) transporters. The proposed mechanism, based on in vitro data, involves decreased clearance due to inhibition of P-gp and BCRP by lasmiditan. The clinical relevance is unknown.
MANAGEMENT: Concomitant use of lasmiditan with drugs that are P-gp and/or BCRP substrates should be avoided when possible. If coadministration is required, patients should be carefully monitored for increased adverse reactions of these drugs and dosing adjusted as necessary.
- "Product Information. Reyvow (lasmiditan)." Lilly, Eli and Company, Indianapolis, IN.
Generic Name: dasabuvir / ombitasvir / paritaprevir / ritonavir
Brand name: Viekira XR, Viekira Pak
Synonyms: Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets, and Dasabuvir
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Ombitasvir, paritaprevir, ritonavir and dasabuvir-Rezira
- Ombitasvir, paritaprevir, ritonavir and dasabuvir-Rh(D) Immune Globulin
- Ombitasvir, paritaprevir, ritonavir and dasabuvir-Rheumatrex
- Ombitasvir, paritaprevir, ritonavir and dasabuvir-Rheumatrex Dose Pack
- Ombitasvir, paritaprevir, ritonavir and dasabuvir-Rheumatrex Dose Pack Oral
- Ombitasvir, paritaprevir, ritonavir and dasabuvir-Rhinall
- Reyvow-Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets
- Reyvow-Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Tablets
- Reyvow-Omeclamox-Pak
- Reyvow-Omega-3 Fatty Acid Capsules
- Reyvow-Omega-3 Fatty Acids
- Reyvow-Omega-3 polyunsaturated fatty acids